Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,006 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu, Human Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

NCT05608005
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
16
States / cities
Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 17, 2026, 5:09 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

NCT02485639
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

NCT03845231
View directory record Official record
Conditions
Influenza
Interventions
Flucelvax(R), Human Challenge virus
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

NCT05227001
View directory record Official record
Conditions
Influenza, Human
Interventions
PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Development of Childhood Anti-Influenza Immunity

NCT03673345
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 17, 2026, 5:09 PM EDT
Withdrawn No phase listed Observational

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

NCT01146353
View directory record Official record
Conditions
Influenza, Renal Failure
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

NCT03694808
View directory record Official record
Conditions
Flu
Interventions
Fluad Vaccine, Fluzone HD Vaccine
Drug
Lead sponsor
David H. Canaday
Other
Eligibility
65 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

NCT00771615
View directory record Official record
Conditions
Influenza
Interventions
GSK A/turkey H5N1 Influenza vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 17, 2026, 5:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

NCT01985997
View directory record Official record
Conditions
Observation Safety
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
Not listed
Enrollment
95,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

P3+ Intervention Phase

NCT02898688
View directory record Official record
Conditions
Vaccination
Interventions
Control Site, Intervention Site, Patient-level Control Group, Patient-level Intervention Group
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
23
States / cities
Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Adults

NCT01938742
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

NCT01857206
View directory record Official record
Conditions
Influenza, Fever
Interventions
Mammalian cell based flu vaccine, Egg based flu vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 17 Years
Enrollment
2,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
18
States / cities
Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

NCT01522248
View directory record Official record
Conditions
Influenza Virus Vaccine
Interventions
Trivalent Inactivated Influenza vaccine
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

FLU-VACS Comparative Study in Adults

NCT00133523
View directory record Official record
Conditions
Influenza
Interventions
Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
2,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
6
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT02124161
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions
13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The FLU-FOBT Program in Primary Care Settings Where Disparities Persist

NCT01211379
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FLU-FOBT Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 75 Years
Enrollment
1,372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Oct 17, 2026, 5:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

NCT04772170
View directory record Official record
Conditions
Influenza, Respiratory Virus, Coronavirus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Inactivated Influenza A/H5N1 Vaccine in the Elderly

NCT00230750
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Torrance, California • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 17, 2026, 5:09 PM EDT
Withdrawn No phase listed Observational

2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies

NCT01270685
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H5N1 Priming and Boosting Strategies

NCT00703053
View directory record Official record
Conditions
Influenza
Interventions
A/Vietnam/1203/04, A/Indonesia/05/05
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
5
States / cities
Decatur, Georgia • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 17, 2026, 5:09 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 17, 2026, 5:09 PM EDT